Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: I am beginning to think

Unless a group is acting seperately but working together

I understand that this must be reported on Schedule 13D of the aggregated holdings of all those working together. Not doing so once the aggregated ownership exceeds reporting criteria could be problematic for any such group.

Corrections more than welcome.

.

.

.

Be well

Share
New Message
Please login to post a reply